Train intensely but allow adequate recovery
AOD-9604, a synthetic fragment derived from the C-terminal region of human growth hormone, has been subjected to extensive clinical evaluation involving over 900 participants across six randomized controlled trials
Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations
People with severe malabsorption, pernicious anemia, or advanced deficiency may not respond adequately to oral supplements alone
As the TRIUMPH Phase 3 trials progress through 2026 and beyond, the full picture of retatrutides efficacy and safety profile will come into sharper focus
14.5 MOUNJARO Use in Combination with Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus SURPASS-PEDS (NCT05260021) was a 30-week double-blind, placebo-controlled trial with a 22-week open-label extension that randomized 99 pediatric patients 10 years of age and older with type 2 diabetes mellitus with inadequate glycemic control on metformin (69%), or basal insulin (8%), or both (23%) to receive subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or placebo once weekly as add-on therapy
